Research
Wolfe Research Initiates Taysha Gene Therapies at Outperform
Taysha Gene Therapies (TSHA) has an average rating of buy and mean price target of $13, according to analysts polled by FactSet.
$TSHA
$TSHA
4 stories mentioning TSHAUpdated 4d ago
Every FINWIRES story that references TSHA, newest first.
What are analysts saying about TSHA?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on TSHA?
Insider Trading
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing
Sukumar Nagendran, Director, President and Head of Research and Development, on July 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $1,248,000. Following the Form 4 filing with the SEC, Nagendran has control over a total of 936,410 common shares of the company, with 936,410 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1806310/000166512426000013/xslF345X05/form4-07102026_100732.xml
$TSHA
Sectors
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Healthcare stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.2% and the iShares Biotechnology ETF (IBB) advancing 0.1%.Bio-Techne (TECH) stock rose more than 20% premarket after the company signed a definitive agreement to be acquired by Germany's Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion.RadNet's (RDNT) shares were down 1.8% pre-bell after rising 3.5% at the prior close. The company's DeepHealth unit said it received FDA 510(k) clearance for two breast imaging AI tools, including a breast arterial calcification assessment and prior exam integration for its ProFound Pro platform.Taysha Gene Therapies (TSHA) stock lost more than 9% after the company priced an underwritten public offering of 32.5 million shares at $6.00 each and pre-funded warrants to purchase 833,333 shares at $5.999 each.
$IBB$RDNT$TECH$TSHA$XLV
Insider Trading
Taysha Gene Therapies Insider Sold Shares Worth $892,000, According to a Recent SEC Filing
Sukumar Nagendran, Director, President, and Head of R&D, on April 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $892,000. Following the Form 4 filing with the SEC, Nagendran has control over a total of 1,136,410 common shares of the company, with 1,136,410 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1806310/000166512426000011/xslF345X05/form4-04132026_080454.xml
$TSHA
